Case Study

Gaining Regulatory Approval Following A Single-Arm Phase I/II Study


A small biotech company engaged Veristat early in clinical development for help with a novel biologic being tested for treatment of an ultra-rare and aggressive hematologic malignancy with no available effective therapies. Using the results of a single-arm Phase I/II study, Veristat and the sponsor company collaborated to present a thorough, well-planned strategy for demonstrating the benefits and risks of the targeted therapy in this patient population to regulatory authorities. Based on Veristat’s significant experience, the sponsor engaged our team for strategic consulting, statistical and programmatic support, and medical writing to plan and execute the marketing application process, eventually leading to both FDA and EMA approval.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene